文献类型： 外文期刊

作者： Pan, Tong ¹ ; Zheng, Shujun ¹ ; Zheng, Weiwei ¹ ; Shi, Chao ¹ ; Ning, Ke ¹ ; Zhang, Qinghui ¹ ; Xie, Yanbo ³ ; Xiang, Hongyu ¹ ; Xie, Qiuhong ¹ ;

作者机构： 1.Jilin Univ, Sch Life Sci, Natl Engn Lab AIDS Vaccine, Changchun, Peoples R China

2.Jilin Univ, Sch Life Sci, Changchun, Peoples R China

3.Jilin Acad Agr Sci, Jilin Prov Key Lab Agr Biotechnol, Changchun, Peoples R China

4.Jilin Univ, Sch Life Sci, Key Lab Mol Enzymol & Engn Minist Educ, Changchun, Peoples R China

5.Jilin Univ, Inst Changbai Mt Resource & Hlth, Fusong, Peoples R China

关键词： traditional Chinese medicine; gut microbiota; type 2 diabetes; FMT; Christensenella; metabolomics

期刊名称：FRONTIERS IN MICROBIOLOGY （ 影响因子：6.064； 五年影响因子：6.843 ）

ISSN：

年卷期： 2022 年 13 卷

页码：

收录情况： SCI

摘要： There is a lot of evidence that oral hypoglycemic drugs work by affecting gut microbes, but the key strains responsible for this effect are not well known. Huang-Qi-Ling-Hua-San (HQLHS), composed of Astragalus Membranaceus, Ganoderma lucidum, Inonotus obliquus, and Momordica charantia L., is a specially designed Chinese medicine formula to treat type 2 diabetes (T2D). In this study, a mouse model of T2D induced by high-fat diet and streptozotocin was used to explore the mechanism of HQLHS in improving hyperglycemia and hyperlipidemia through multiple rounds of animal experiments, such as HQLHS feeding, fecal microbiota transplantation (FMT), and live bacteria feeding, so as to explore the potential target intestinal flora in its hypoglycemic effect. Results show that such specific taxa as Bifidobacterium, Turicibacter, Alistipes, Romboutsia, and Christensenella were identified to be preferably enriched by HQLHS and then assumed to be the target microbes. Herein, FMT was used to test if the upregulated beneficial bacteria by HQLHS play a therapeutic role. The strain Christensenella minuta DSM 22607 and the strain Christensenella timonensis DSM 102800 were selected to test the beneficial effect of Christensenella taxa on T2D. Diabetic animals supplemented with these strains showed the improvement in blood glucose and lipid metabolism, the promotion of GLP-1 secretion, the increase in antioxidant capacity, the inhibition of hepatic gluconeogenesis, the suppression of intestinal glucose absorption, the enhancement of intestinal barrier, reduced LPS-induced inflammation, and the reduction of branched amino acids (BCAAs) content in the liver. Overall, these data demonstrate that Christensenella plays a beneficial role in T2D and is a target for the action of HQLHS therapy.